Related Experiment Video
Updated: Sep 9, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
The 2025 AHA/ACC Hypertension Guidelines: Key Updates, Historical Context, and Clinical Implications
John M Giacona1,2,3, Wanpen Vongpatanasin4,5
1Hypertension Section, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA. john.giacona@utsouthwestern.edu.
Purpose Of Review:
This review examines the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, placing its recommendations in historical context and evaluating the supporting evidence across major clinical populations.
Recent Findings:
The 2025 guideline retains the 2017 blood pressure categories and treatment goal of less than 130/80 mmHg but introduces the race-free PREVENT equations, uses a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension, and encourages systolic blood pressure below 120 mmHg in selected high-risk patients. Additional updates include single-pill combination therapy for stage-2 hypertension, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio measurement, removal of race-based drug selection, and cautious incorporation of renal denervation. Recent trials strengthen the evidence for intensive lowering, including in diabetes and older adults. The 2025 guideline advances a risk-based, measurement-dependent approach. The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up at scale.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
Hypertension I: Introduction
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension and Regulation of Blood Pressure